SYRE news

Spyre Therapeutics announced Q3 2026 financials, highlighting potential best-in-class candidate SPY003 for IBD and announcing a $400M public offering to advance its HS program.

Spyre Therapeutics entered into an underwriting agreement to sell an aggregate of 4,117,648 shares of common stock, with an option for an additional 617,647 shares. The offering will be led by Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated,…

Spyre reported positive Phase 2 SKYLINE data for SPY003, a potential best-in-class anti-IL-23. The results met its endpoints with clinically meaningful improvements and a well-tolerated safety profile.

Spyre Therapeutics restated its ESPP to reserve 1,056,096 shares for eligible employees and participating corporations. The plan amendment enhances employee equity participation and includes provisions for both Section 423 and Non-Section 423 components for international operations.